Revolutionizing Peptide Drugs with Radical Enzymes | Dr. Karsten Eastman, Ph.D. - CEO and Co-Founder, Sethera Therapeutics

Send us Fan MailDr. Karsten Eastman, Ph.D. is the CEO and Co-Founder of Sethera Therapeutics ( https://setheratx.com/ ), a company focused revolutionizing peptide-based drug development with a cutting-edge enzymatic cross-linking technology, and their platform enables the synthesis of highly stable, polymacrocyclic peptides designed to engage multiple targets simultaneously, offering unparalleled precision in therapeutic design.Trained as a chemist at the University of Utah, where he earned his PhD in 2023, Dr. Eastman has built his career at the intersection of peptide synthesis, protein engineering, and radical enzymology. His work focuses on understanding how enzymes choreograph complex molecular transformations — and then harnessing those principles to build programmable, drug-like molecules.In collaboration with researchers at the University of Utah, Dr. Eastman and his team recently published in Proceedings of the National Academy of Sciences a breakthrough discovery involving PapB, a radical S-adenosyl-L-methionine (SAM) enzyme capable of installing precise, durable thioether “staples” into peptides in a single enzymatic step. This work opens vast new chemical space for macrocyclic peptide therapeutics and offers a powerful new approach to targeting diseases long considered “undruggable.”At Sethera Therapeutics, Dr. Eastman is translating this enzymatic platform into next-generation peptide medicines that aim to combine the selectivity of biologics with the drug-like properties of small molecules.#PeptideTherapeutics #DrugDiscovery #Biotechnology #Enzymology#RadicalSAM #PapB #SetheraTherapeutics #UndruggableDiseases#MacrocyclicPeptides #Bioengineering #Therapeutics #Innovation #ScienceBreakthrough #PeptideDrugs #EnzymeTechnologySupport the show